OncoMed Pharmaceuticals — Merger or Acquisition (March 2019)
19 slides from OncoMed Pharmaceuticals's merger presentation, Mar 12, 2019
Slide 1: Mereo BioPharma: Improving Outcomes for Patients with Rare Diseases
March 2019 MEREO BIOPHARMA IMPROVING OUTCOMES FOR PATIENTS WITH RARE DISEASES
Slide 2: Disclaimer
DISCLAIMER 1 Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe f or or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any
Slide 3: Forward Looking Statements
FORWARD LOOKING STATEMENTS 2 Mereo BioPharma Group plc Forward - Looking Statements This communication contains “forward - looking statements.” All statements other than statements of historical fact contained in t his report are forward - looking statements within the meaning of Section 27A of the
Slide 4: Corporate and Commercial Strategy
3 CORPORATE AND COMMERCIAL STRATEGY Mereo BioPharma Group plc The core strategy of the combined business will continue to focus on Orphan Drugs & Rare Diseases Potential new products Core Rare Disease Strategy Bone/ Musculoskeletal Endocrine Respiratory BPS - 804 Setrusumab MPH - 966 Alvelestat Pote
Slide 5: Strategic Rationale for the Combination
STRATEGIC RATIONALE FOR THE COMBINATION 4 • Three phase 2 readouts in core orphan products in 2019 ( Mereo’s BPS - 804 and MPH - 966) • Potential partnerships of Mereo’s BCT - 197 and BGS - 649 programs • Potential partnership of OncoMed’s navicixizumab • Ongoing Celgene collaboration with an option
Slide 6: Osteogenesis Imperfecta (OI)
Mereo BioPharma Group plc OSTEOGENESIS IMPERFECTA (OI) 5 An orphan genetic chronic bone disorder characterised by fragile bones that break easily ̴ 6.2 OI cases per 100,000 population in the US 1 ̴ 10 OI cases per 100,000 population in the EU 2 Prevalence: 85% - 90% linked to a gene mutation that pr
Slide 7: OI Treatment: Drugs Used – None FDA or EMA Approved for OI
OI TREATMENT: DRUGS USED – NONE FDA OR EMA APPROVED FOR OI ▪ Bisphosphonates ▪ Alendronate, risedronate, pamidronate, zoledronate, etc. ▪ Approved for treatment of adult osteoporosis ▪ Synthetic analogues of pyrophosphate ▪ Inhibit bone resorption ▪ Can be given orally or intravenously, depending on
Slide 8: Adult Phase 2b Study
BPS - 804 ADULT PHASE 2B STUDY 7 Completed enrolment: Trial arms: Study duration: 112 OI Patients Types I, III and IV 6 months open label data 1H 2019 with 12 months H2 2019 Top line data from three blinded arms by the end of 2019 Three different monthly dosing regimens of BPS - 804 Open label arm a
Slide 9: HRpQCT Scans of Patients with OI and Controls
HRPQCT SCANS OF PATIENTS WITH OI AND CONTROLS 8 Mereo Biopharma Group plc
Slide 10: Pediatric Phase 3 Study
BPS - 804 – PEDIATRIC PHASE 3 STUDY 9 Planned enrolment: 24 patients 5 - 18 years Total Study duration ~ 160 Severe OI Patients Types I, III and IV Initiation in 2019 first in EU and Canada Patients on bisphosphonate therapy One month dose finding – 3 doses versus placebo Additional 128 patients Ran
Slide 11: Regulatory Strategy
BPS - 804 REGULATORY STRATEGY 10 Orphan drug status EU and US PIP agreed with EMA Admitted to the Adaptive Pathway and PRIME in the EU • Ongoing interactive dialogue with EMA and HTA’s • Real world evidence/registries Plan to engage with the FDA on extending the pediatric Phase 3 trial to sites in t
Slide 12: Alpha-Antitrypsin Deficiency (AATD)
Mereo BioPharma Group plc ALPHA - 1 ANTITRYPSIN DEFICIENCY (AATD) An orphan genetic disorder that results in pulmonary disease North America ~ 50,000 Europe ~60,000 Estimated prevalence of target patients ( PiZZ and Nulls) Symptoms: • Age 20 - 50 - wheeze and reduced exercise tolerance • PiZZ and Nu
Slide 13: Restoring the Balance in Alpha-1 Lung Disease with Alvelestat
Mereo BioPharma Group plc RESTORING THE BALANCE IN ALPHA - 1 LUNG DISEASE WITH NEUTROPHIL ELASTASE INHIBITOR - ALVELESTAT 12 Elastase Anti - Elastase Alpha - 1 antitrypsin Alvelestat
Slide 14: MPH-966 Proof of Concept Phase 2 Study
MPH - 966 – PROOF OF CONCEPT PHASE 2 STUDY • Three - arm study with two different dosing arms versus placebo • Planned enrolment - 165 patients completed • Treatment duration - 12 weeks • FPI in November 2018 Primary Endpoint • Desmosine - biomarker shown to have correlation with lung density by CT
Slide 15: BCT-197 Met the Primary Endpoint in the Phase 2 Trial
14 PRIMARY ENDPOINT (CHANGE IN FEV1 FROM BASELINE TO DAY 7 WITHIN THE TREATMENT GROUP) Primary endpoint met on an ITT basis for both high and low dose regimens (p= 0.012, p ≤ 0.001) versus no significant change from baseline (p=0.102) for Standard of Care plus placebo POSITIVE CLINICAL AND HEALTH EC
Slide 16: BGS-649 Met the Primary Endpoint in the Phase 2b Trial
BGS - 649 MET THE PRIMARY END POINT IN THE PHASE 2 B TRIAL TOTAL OF 271 PATIENTS 15 PRIMARY ENDPOINT : normalisation of testosterone @ 24 wk in > 75 % subjects at all three doses p< 0.001 versus placebo with no patient > 1500 ng/dl at any time point SECONDARY ENDPOINTS Change in fertility hormones (
Slide 17: Combined Group Cash Runway Extended into 2020
COMBINED GROUP CASH RUNWAY EXTENDED INTO 2020 16 Key go forward funding priorities Funding commitment ended in 2018 Trials ended/ending BCT - 197 Phase 2: Completed BGS - 649 Phase 2b: completes this year NAVI Phase 1b Etigilimab (anti - TIGIT) Phase 1a GITRL - Fc Trimer Key ongoing studies BPS - 80
Slide 18: Mereo Upcoming Key Milestones
Mereo BioPharma Group plc 17 2019 2020 2021 BPS - 804 MPH - 966 Partnering BCT - 197 BGS - 649 NAVI ANTI - TIGIT Additional Rare Disease Products MEREO UPCOMING KEY MILESTONES Pediatric Pivotal 12 month fracture Partnering (Regulatory) New product opportunities 6m Adult HRPqCT data 12m 12m Phase 2 P
Slide 19: Contact: One Cavendish Place, London
Mereo BioPharma Group plc One Cavendish Place London, W1G 0QF UK +44 (0)333 0237 300
OncoMed Pharmaceuticals — Merger or Acquisition (March 2019) on 6ix